Qiming Venture Partners Wins Eight Awards in Zero2IPO's 2025 Rankings, Including Third Place Among China's Top VC Firms

Recently, the highly anticipated Zero2IPO 2025 China Equity Investment Annual Rankings were unveiled. Compiled with rigorous research methodology and a commitment to fairness, these rankings aim to provide the Chinese equity investment industry with a robust framework for evaluation and benchmarking. Qiming Venture Partners and its Managing Partner William Hu received eight awards. Notably, Qiming Venture Partners entered the top three of China's annual venture capital firms for the first time, marking its ninth consecutive year in the top ten.

Qiming Venture Partners

Received

No. 3 Annual China Venture Capital Firm

William Hu, Managing Partner of Qiming Venture Partners

Received

Top 10 Annual China Venture Capitalists

Qiming Venture Partners

Received

Top 50 Annual China "Specialized, Refined, Differential, and Innovative" Investment Firms

Top 30 Annual China Advanced Manufacturing Investment Firms

Top 30 Annual China Healthcare Investment Firms

Top 20 Annual China Artificial Intelligence Investment Firms

Top 20 Annual China Digital Economy Investment Firms

Insta360, a Qiming Venture Partners portfolio company

Received

Annual China Most Influential VC/PE-Backed IPO Case

Selection Criteria

Zero2IPO Research Center leverages its professional SaaS system for private equity investment — Pedata — employing professional, scientific, and quantifiable methods to analyze and filter from multiple angles. The final rankings for 2025 cover four major categories: VC/PE comprehensive awards, sector-specific awards, outstanding case awards, and intermediary awards, comprising dozens of lists in total, all based on detailed data, real market conditions, and scientific standards to comprehensively and accurately reflect market development and competitive landscape.

To date, Qiming Venture Partners manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its founding, the firm has focused on investing in outstanding early- and growth-stage companies in technology and healthcare innovation.

Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on major global exchanges or exited through M&A and other means, and over 80 have become recognized unicorns or super-unicorns.

At the 25th China Equity Investment Annual Forum, William Hu noted that Qiming Venture Partners concentrates on two core sectors: technology and healthcare innovation. In technology, the application layer of artificial intelligence represents the greatest opportunity and has been the firm's primary investment focus this year. Healthcare innovation investments center on the globalization of China's pharmaceutical R&D capabilities, spanning innovative drugs and medical devices. Qiming Venture Partners continues to support its portfolio companies in integrating into the global healthcare industry chain.

Source | Zero2IPO Research

Past Highlights

Qiming Honors | Qiming Venture Partners Ranked No. 5 in Zero2IPO 2024 Annual China Venture Capital Firms and Received Four Other Awards Qiming Honors | Qiming Venture Partners and Investors Receive Shanghai Securities News 2025 "Golden Eagle · Financial Capital" Awards Qiming Honors | Qiming Venture Partners Receives Three Awards at China Venture Capital Research Institute · 2025 China Venture Capital Industry Annual Golden Investment Awards

Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its founding, Qiming has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means, and over 80 have become recognized unicorns or super-unicorns.

Among Qiming Venture Partners' portfolio companies, many have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hepaloc Therapeutics, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.